NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

WILMINGTON, Del: NRx Pharmaceuticals, Inc. has issued the following news release: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ('NRx', the 'Company'), a clinical-stage biopharmaceutical company, today announced the transmission of first section [...]